Stuart Oliver

1.4k citations

29 papers · 1.1k indexed · h-index 17

Impact in

Internal Medicine top 5%
- Venous Thromboembolism Diagnosis and Management
Infectious Diseases top 10%
- Antifungal resistance and susceptibility

Papers in ⓘ

Pharmacology 5
- Pharmacogenetics and Drug Metabolism 5
- Antibiotics Pharmacokinetics and Efficacy 4
Hematology 6
- Acute Myeloid Leukemia Research 3
- Chronic Myeloid Leukemia Treatments 3

Co-authors: Kathleen Butler (1 shared paper)Renli Teng (1 shared paper)Martin A. Hayes (1 shared paper)Lynn Purkins (2 shared papers)Nolan Wood (2 shared papers)Michael J. Allen (3 shared papers)Chris Ward (3 shared papers)Paul Martin (7 shared papers)
Journals: British Journal of Clinical Pharmacology (4 papers)Clinical Therapeutics (4 papers)Antimicrobial Agents and Chemotherapy (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Drug Metabolism and Disposition (2 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Stuart Oliver

29 papers receiving 1.1k citations

Peers

Countries citing papers authored by Stuart Oliver

Since Specialization

Citations

This map shows the geographic impact of Stuart Oliver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Oliver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Oliver more than expected).

Fields of papers citing papers by Stuart Oliver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Oliver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Oliver. The network helps show where Stuart Oliver may publish in the future.

Co-authors

The 25 scholars most cited alongside Stuart Oliver, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stuart Oliver Line = papers co-authored together Stuart Oliver links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects Drug Metabolism and Disposition ·Renli Teng, Stuart Oliver, Martin A. Hayes, Kathleen Butler	2010	213
2	Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety British Journal of Clinical Pharmacology ·Lynn Purkins, Nolan Wood, Katie Greenhalgh, Michael J. Allen, Stuart Oliver	2003	123
3	Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers The Journal of Clinical Pharmacology ·John D. Iuliucci, Stuart Oliver, Steven K. Morley, Chris Ward, Janet Ward, David C. Dalgarno, Tim Clackson, Harvey J. Berger	2001	98
4	The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent British Journal of Clinical Pharmacology ·Lynn Purkins, Nolan Wood, Katie Greenhalgh, Malcolm D. Eve, Stuart Oliver, D. J. Nichols	2003	92
5	Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects Clinical Therapeutics ·Paul Martín, Stuart Oliver, Sarah-Jane Kennedy, E. A. Partridge, Michael G. Hutchison, David S. Clarke, Petrina B. Giles	2011	67
6	Pharmacokinetics and Tolerability of Gemifloxacin (SB-265805) after Administration of Single Oral Doses to Healthy Volunteers Antimicrobial Agents and Chemotherapy ·Ann Allen, Elizabeth Bygate, Stuart Oliver, Martin Johnson, Chris Ward, Ae-Jin Cheon, Youn Sung Choo, In-Chull Kim	2000	57
7	Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia Cancer Chemotherapy and Pharmacology ·Mike Dennis, Michelle Davies, Stuart Oliver, R. A. D'Souza, Laura A. Pike, Paul K. Stockman	2012	53
8	Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine Clinical Pharmacokinetics ·Susanne Johansson, Jessica Read, Stuart Oliver, Mark L. Steinberg, Yan Li, Eleanor Lisbon, David Mathews, Philip T. Leese, Paul Martin	2014	52
9	Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML Clinical Lymphoma Myeloma & Leukemia ·Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag, Philippe Rousselot, Guillermo Garcia‐Manero, Elias Jabbour, Kate Owen, Paul K. Stockman, Stuart Oliver	2013	46
10	Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole Drugs in R&D ·Paul Martin, Stuart Oliver, Jane Robertson, Sarah-Jane Kennedy, Jessica Read, Thierry Duvauchelle	2011	40
11	The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing British Journal of Clinical Pharmacology ·Michael J. Allen, Donald J. Nichols, Stuart Oliver	2000	34
12	A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects Clinical Pharmacology in Drug Development ·Kelong Han, Jennifer Cremer, Robert C. Elston, Stuart Oliver, Sharon Baptiste‐Brown, Shuguang Chen, David Gardiner, Matt Davies, Joanne Saunders, Robert Hamatake, Jan Losos, Martin Leivers, Steve R. Hood, Frans van den Berg, Melanie Paff, James M. Ritter, Dickens Theodore	2019	34
13	Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies PubMed ·Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada, Thomas Morris	2011	27
14	Multiple-Dose Pharmacokinetics and Tolerability of Gemifloxacin Administered Orally to Healthy Volunteers Antimicrobial Agents and Chemotherapy ·Ann Allen, Elizabeth Bygate, Marika Vousden, Stuart Oliver, Martin Johnson, Chris Ward, Ae-Jin Cheon, Youn Sung Choo, In-Chull Kim	2001	27
15	Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment Clinical Pharmacokinetics ·Angelika Weil, Paul Martin, Robert P. Smith, Stuart Oliver, Peter Langmuir, Jessica Read, K H Molz	2010	26
16	Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer Investigational New Drugs ·Michael Michael, Peter Gibbs, Robert P. Smith, A. Godwood, Stuart Oliver, Niall C. Tebbutt	2008	22
17	Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study Cancer Chemotherapy and Pharmacology ·Mark Saunders, Richard H. Wilson, Marc Peeters, Robert P. Smith, A. Godwood, Stuart Oliver, Eric Van Cutsem	2009	18
18	Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies Drugs in R&D ·Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Elliott B. Grossbard, Muhammad Baluom, David Lau, David J. Sweeny, Tim Mant, Kelli Craven	2016	15
19	Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies Clinical Therapeutics ·Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Robert Elsby, Muhammad Baluom, David T. W. Lau, Tim Mant	2015	15
20	Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML) Blood ·Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag, Philippe Rousselot, Guillermo Garcia‐Manero, Elias Jabbour, Kate Owen, Paul K. Stockman, Stuart Oliver	2010	13

About Stuart Oliver

Stuart Oliver is a scholar working on Pharmacology, Hematology, Molecular Medicine, Pharmacology and Oncology, having authored 29 papers that have together received 1.1k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Cancer Treatment and Pharmacology (3 papers), Acute Myeloid Leukemia Research (3 papers), Hormonal and reproductive studies (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). The work is most often cited by research in Internal Medicine (75 citations), Infectious Diseases (232 citations), Cardiology and Cardiovascular Medicine (246 citations), Pharmacology (176 citations) and Pharmacology (86 citations). Stuart Oliver has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Kathleen Butler, Renli Teng, Martin A. Hayes, Lynn Purkins, Nolan Wood, Michael J. Allen, Chris Ward, Paul Martin, Jessica Read and Paul K. Stockman. Their work appears in journals such as British Journal of Clinical Pharmacology, Clinical Therapeutics, Antimicrobial Agents and Chemotherapy, Cancer Chemotherapy and Pharmacology and Drug Metabolism and Disposition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact